Cybin completes enrollment in phase 2 DMT anxiety study
PositiveFinancial Markets

Cybin has successfully completed enrollment for its phase 2 study on DMT for anxiety, marking a significant step in exploring innovative treatments for mental health. This study is crucial as it could pave the way for new therapeutic options for individuals struggling with anxiety disorders, potentially transforming the landscape of mental health treatment.
— Curated by the World Pulse Now AI Editorial System